Comment from REMS Industry Consortium

Summary: The REMS Industry Consortium (RIC) supports the FDA's draft guidance on using artificial intelligence for regulatory decision-making. They specifically applaud the risk-based credibility assessment framework and the FDA's commitment to early engagement with sponsors and stakeholders.